8-K
filed May 19, 2023, 7:59 PM ET
ticker ATYR
CIK 0001339970
other material
confidence high
sentiment neutral
materiality 0.50
aTyr Pharma stockholders approve doubling of authorized shares and equity plan increase
aTYR PHARMA INC
- Authorized common shares increased from 85M to 170M via Charter Amendment filed May 18, 2023.
- 2015 Stock Plan share reserve increased by 4M shares to 7,711,868 (post-reverse split).
- Two Class II directors elected: Timothy P. Coughlin and Jane A. Gross, Ph.D., until 2026.
- Ernst & Young ratified as independent auditor for FY 2023 with 44.5M votes for.
- Advisory say-on-pay compensation approved with 37.2M for, 1.0M against.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
aTYR PHARMA INC: Increased authorized shares of common stock from 85,000,000 to 170,000,000 via Certificate of Amendment to Restated Certificate of Incorporation (effective 2023-05-18).
- Change
- charter amendment
- Effective
- 2023-05-18
Exact text from the filing
On May 18, 2023, following stockholder approval of the Authorized Share Proposal at the Annual Meeting, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation (the “Charter Amendment”) to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
aTYR PHARMA INC: Board approved and adopted amendments to the Code of Business Conduct and Ethics to augment compliance protections and clarity (effective 2023-05-17).
- Change
- code of ethics
- Effective
- 2023-05-17
Exact text from the filing
On May 17, 2023, the Board adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics, as reflected in an amended version of the Code of Business Conduct and Ethics (the “Code”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Election of two Class II directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1 – Election of Class II Directors. Director Nominee Votes For Withhold Broker Non-Vote Timothy P. Coughlin 34,867,452 3,431,326 6,317,414 Jane A. Gross, Ph.D. 34,876,816 3,421,962 6,317,414
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
Proposal 2 – Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstain Broker Non-Vote 44,505,484 99,431 11,277 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000.
- Proposal
- charter amendment
- Outcome
- passed
Exact text from the filing
Proposal 5 – Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000. Votes For Votes Against Abstain Broker Non-Vote 41,984,002 518,951 2,113,239 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. Votes For Votes Against Abstain Broker Non-Vote 37,246,069 1,007,212 45,497 6,317,414
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Approval of an amendment to the 2015 Stock Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 4 – Approval of an amendment to the 2015 Stock Plan. Votes For Votes Against Abstain Broker Non-Vote 30,235,893 8,020,783 42,102 6,317,414
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
aTYR PHARMA INC shareholders approved Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5.
- Outcome
- passed
Exact text from the filing
Proposal 6 – Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5. Votes For Votes Against Abstain Broker Non-Vote 36,384,724 8,179,700 51,768 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.